how janssen optimizes the stability of a therapeutic mab
Published 5 months ago • 48 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
12:14
optimizing stability during the formulation of therapeutic proteins
-
23:45
measuring stability to more effectively select therapeutic antibody candidates
-
3:32
monoclonal antibodies and its production
-
30:05
the new gold standard in biologic characterization – develop your biologics better with prometheus
-
1:26
emerging monoclonal antibodies for the treatment of multiple myeloma
-
4:38
benefits of monoclonal antibody treatment
-
3:33
in-depth: what are monoclonal antibodies and how do they work?
-
41:06
formulation and stability screening of biotherapeutics
-
17:13
chronic lymphocytic leukemia treatment & side effects (venetoclax & obinutuzumab) | tamsin (3 of 3)
-
13:24
case study - downstream processing of monoclonal antibodies produced in bioreactors
-
2:45
what are the practical considerations for monoclonal antibody infusion?
-
4:37
monoclonal antibody treatment: education training
-
0:44
what is a monoclonal antibody?!
-
1:11:37
scientific evaluation and due diligence of innovative monoclonal antibody therapeutics
-
5:35
optimized purity of a monoclonal antibody using mixed-mode chromatography media
-
2:08
a closer look at monoclonal antibody treatment
-
23:00
john desjarlais: "optimization and application of fc-containing bispecific antibodies"
-
43:38
webinar - bispecific antibodies: the next generation of antibody therapeutics
-
1:03:04
netec: monoclonal antibody therapy in residential healthcare settings
-
2:40
monoclonal antibodies: the future of mm treatment?
-
38:44
zoomab® antibodies- a novel recombinant antibody technology
-
1:01:10
brian fonslow - comprehensive characterization of mabs in a single analysis